Gumboro disease, as a resident virus, is already present inside the farm, in the litter, or before the day-old chicks are released onto the floor, so the probability of challenge for most farms is very high. The characteristics of this challenge (age, severity, consequences, etc.) will vary from poultry house to poultry house, but the disease challenge will definitely occur.
In this situation, it is understandable that vaccination should aim at both protecting the broilers and preventing the challenge from getting out of control, that is, at ‘controlling’ the Gumboro Disease.
Key approaches that should be considered for complete Gumboro Disease management:
For the very initial protection of the chicks, it means the first 2 weeks of age, the MDAs (Maternal delivered antibodies) will be essential. But after the decrease of the MDA level the chick should build up their own active immunity.
To generate the active immunity, the name of the game on controlling IBD will be through vaccination. By blocking the bursa, by the replication of the vaccine virus, and this way preventing the field strains from infecting the chick.
The Figure below shows what the objectives of Gumboro vaccination programme should be.
For this, a live virus must be used, so that this block actually occurs. The strain used in the immune-complex IBD vaccine, as the W2512, must be attenuated and maintain its invasiveness without generating any kind of permanent damage to the cells of the bursa. It is important to note that the lymphoid depletion generated by intermediate or intermediate plus strains, in which a decrease in bursa size is observed, is physiological and transient, not impacting the immune system of birds.
At the same time, this virus must be protected by antibodies (Virus Protecting Immunoglobulins VPI) so that the release occurs at the right time, and the inactivation of this vaccine virus does not occur, as in the Immune-complex IBD vaccines. A correct balance between the IBD virus and the anti IBDV antibodies is of crucial importance for the efficacy and safety of these vaccines.
The immune-complex vaccine, as Transmune, have the ability to fully colonise the bursa, protect against all field IBD viruses and overcome MDA; some of the key advantages of the immune-complex vaccines. The vaccine take occurs when the MDA level decreases to a point that allows the vaccine virus to be released and to reach the bursa of Fabricius. From this moment on, the vaccine strain will replicate in the bursa of Fabricius and the chicken will be immunised against any type of IBD virus. The fact that the virus is covered by VPI´s is important to maintain safety and stability in chickens with varying levels of maternal antibodies. In case of low levels of MDAs, replication of the vaccine virus will occur earlier, and in birds with higher levels of MDA, it will occur later. In all birds thus adapted according to the most appropriate time for replication, and thus onset of active immunity.
Understanding the important to block the bursa by a live vaccine, and in this way prevent the build-up of a higher virus pressure, cycle after cycle, and stop the evolution of the IBD virus towards a form that could escape the prevention programme.
These are the consequences of the ‘protection against shedding’. In other words, the objectives of a sound Gumboro vaccination programme should aim at stopping the Gumboro cycle. To achieve the stop of the Gumboro disease, the vaccination programme should be well fitted.
As summary, to have IBD control and keep the consistency of the broiler production, provide protection against clinical and sub-clinical infection, and prevention of field virus replication is essential. But it should be done with safety, as the immune-complex vaccine Transmune, that adapts to different maternal delivered antibodies levels, blocking the bursa for a better Gumboro disease control.
Ceva Santé Animale (Ceva) is the 5th global animal health company, led by experienced veterinarians, whose mission is to provide innovative health solutions for all animals to ensure the highest level of care and well-being. Our portfolio includes preventive medicine such as vaccines, pharmaceutical and animal welfare products for farm and companion animals, as well as equipment and services to provide the best experience for our customers. With 6,500 employees located in 47 countries, Ceva strives daily to bring to life its vision as a OneHealth company: “Together, beyond animal health”. 2022 turnover: €1.53 billion. Use the links below to learn more about Ceva.
Ceva Santé Animale (Ceva) is the 5th global animal health company, led by experienced veterinarians, whose mission is to provide innovative health solutions for all animals to ensure the highest level of care and well-being. Our portfolio includes preventive medicine such as vaccines, pharmaceutical and animal welfare products for farm and companion animals, as well as equipment and services to provide the best experience for our customers. With 6,500 employees located in 47 countries, Ceva strives daily to bring to life its vision as a OneHealth company: “Together, beyond animal health”. 2022 turnover: €1.53 billion. Use the links below to learn more about Ceva.
Notifications
Your Privacy Matters
It's your legal right to choose which information a website may store and have access to. With your permission, we and our third-party partners (19) store and/or access information on a device, such as unique identifiers in cookies and browsing data to collect and process personal data.
We and our partners do the following data processing:
Store and/or access information on a device, Advertising based on limited data and advertising measurement, Personalised content, content measurement, audience research, and services development
If you accept any or all of these, you will have agreed to this website's use of cookies for these purposes. You may also choose to refuse consent, but certain personalized features of the site won't be available to you.